Opinion
Video
Patient Cases Treated with a Ranibizumab Biosimilar
Author(s):
Dilsher Dhoot, MD, presents two cases involving DME and CRVO, that show remarkable anatomical improvement with a biosimilar comparable to those achieved with reference biologics.
This is a video synopsis/summary of a panel discussion involving Dilsher S. Dhoot, MD.
A retina specialist presents 2 cases discussed at a roundtable, starting with a 73-year-old Caucasian female with neovascular macular degeneration. Initially presenting with a vision of 20/30, posterior segment examination revealed drusen and RPE (retinal pigment epithelium) changes. A month later, the patient reported central scotoma and decreased visual acuity to 20/30, with OCT showing thickening and edema. A biosimilar, ranibizumab, was initiated, leading to significant improvement in subsequent follow-ups, with the patient's vision improving to 20/20-1. The positive response prompted continued treatment with biosimilars.
The second case involves a 79-year-old female with central retinal vein occlusion, presenting with 20/100-1 vision and central vision disturbances. The anterior segment exam revealed pseudophakia, and the posterior segment exam showed typical signs of central retinal vein occlusion. After dosing with a biosimilar, ranibizumab, the patient showed improvement in anatomy and vision, with subsequent doses of biosimilar ranibizumab leading to continued stability and improved vision (20/60).
In both cases, the expert emphasizes the successful outcomes achieved through biosimilar treatments, showcasing improvements in visual acuity, anatomical changes, and patient satisfaction. The cases underscore the efficacy and potential for extending treatment with biosimilars in retinal diseases. The use of ranibizumab proves to be a valuable therapeutic option in managing neovascular macular degeneration and central retinal vein occlusion.
Video synopsis is AI-generated and reviewed by Ophthalmology Times editorial staff.
